Anzeige
Mehr »
Login
Samstag, 15.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Pioneer AIs Partner Cykel AI treibt KI-basierte Personalbeschaffung mit dem autonomen Agenten Lucy voran!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J68D | ISIN: CNE100001M79 | Ticker-Symbol: 08HH
Tradegate
14.03.25
15:55 Uhr
1,743 Euro
-0,056
-3,11 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,8121,82714.03.
1,7511,84614.03.

Aktuelle News zur SHANGHAI FOSUN PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrFosun Pharma verkauft Anteil an Krankenhausgruppe für 124,08 Mio. US-Dollar an Warburg Pincus - Nikkei2
FrFosun Pharma offloads $124m stake in hospital group to Warburg Pincus - Nikkei16
FrChina's Fosun Pharma to Sell United Family Healthcare to Calcite Gem for USD124 Million9
DoFOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL OF DRUG CLINICAL TRIAL OF A SUBSIDIARY4
DoFOSUN PHARMA (02196): DATE OF BOARD MEETING6
06.03.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION7
04.03.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL OF VACCINE CLINICAL TRIAL OF A SUBSIDIARY10
SHANGHAI FOSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln
04.03.Raziel Therapeutics: Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")334REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces...
► Artikel lesen
27.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL OF DRUG CLINICAL TRIAL OF A SUBSIDIARY3
26.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A SUBSIDIARY1
26.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION1
26.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A LICENSED PRODUCT2
20.02.FOSUN PHARMA (02196): CONNECTED TRANSACTION - ENTERING INTO THE CAPITAL INCREASE AGREEMENT9
17.02.FOSUN PHARMA Self-developed PharmAID Decision Agent Platform Links to Deepseek R17
10.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION6
06.02.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL OF DRUG CLINICAL TRIAL OF A SUBSIDIARY3
03.02.FOSUN PHARMA (02196): NEXT DAY DISCLOSURE RETURN - SHARE BUYBACK5
24.01.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION12
23.01.China's Fosun Pharma Shelves Plan to Take Unit Henlius Private Due to Shareholder Opposition9
23.01.FOSUN PHARMA (02196): NEXT DAY DISCLOSURE RETURN - SHARE BUYBACK17
Seite:  Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1